SENS News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

SE

Mkt Cap

$435.2M

Volume

507.72K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Beta Bionics Stock Down Despite iLet-Eversense 365 Integration DealBeta Bionics announced a partnership with Senseonics to integrate the Eversense 365 continuous glucose monitor with its iLet and future mint AID systems. The integration, launching in Q4 2026, will make iLet compatible with more CGM manufacturers than any other AID system. Despite the strategic partnership, BBNX shares fell over 8% following the announcement.Zacks Investment Research · Sep 29, 2026

Global Blood Glucose Monitoring System Market Size to Reach USD 39.4 Billion by 2035 | Growing at 8.9% CAGR | Industry Trends, Market Share & Forecast – Custom Market InsightsThe global blood glucose monitoring system market is valued at USD 16.8 billion in 2025 and is projected to reach USD 39.4 billion by 2035, growing at a CAGR of 8.9%. Growth is driven by AI-enabled monitoring systems, increasing diabetes prevalence, and rising adoption of home healthcare solutions. Key players include Medtronic, Abbott, Dexcom, and Roche, with recent partnerships like Abbott-Medtronic collaboration to integrate continuous glucose monitoring with automated insulin delivery systems.GlobeNewswire Inc. · Jul 14, 2026

Senseonics Announces Pricing of $80 Million Public Offering of Common Stock and Pre-Funded WarrantsSenseonics Holdings announced a $80 million underwritten public offering of 8 million shares at $5.00 per share and pre-funded warrants. The offering is expected to close on May 4, 2026. Net proceeds will fund the launch of Eversense 365 and development of pipeline products.GlobeNewswire Inc. · May 1, 2026

Middle East and Africa Continuous Glucose Monitoring Market Forecast and Company Analysis Report 2026-2034 Featuring Dexcom, Medtronic, Senseonics, Abbott Diabetes Care, and GlySensThe Middle East and Africa CGM market is projected to grow from USD 320.44 million in 2025 to USD 855.30 million by 2034 at an 11.53% CAGR, driven by rising diabetes prevalence, healthcare infrastructure improvements, and digital health integration. Key growth factors include government initiatives promoting preventive care and increasing smartphone adoption for remote monitoring, though high device costs and limited reimbursement remain barriers.GlobeNewswire Inc. · Apr 29, 2026

Senseonics Announces European Launch of Eversense® 365, The World’s First and Only One Year CGM SystemSenseonics launched its Eversense 365 continuous glucose monitoring system in Sweden with planned rollouts in Germany, Spain, and Italy. The implantable CGM doubles sensor lifespan to one year compared to its predecessor and reduces calibration frequency from daily to weekly. The company reported Q4 2025 revenue of $14.3 million, a 72% year-over-year increase, and announced integration with Sequel Med Tech's automated insulin delivery system.GlobeNewswire Inc. · Apr 24, 2026

MedTech's Edge: How AI and Remote Diagnostics Drive Scalable ValueThe healthcare sector is shifting toward outpatient clinics and ambulatory services, with AI-powered diagnostics and remote care technologies gaining significant traction. Multiple medtech companies are advancing innovative solutions: VentriPoint Diagnostics is expanding cardiac imaging to remote communities via partnership with First Light Health; Senseonics demonstrated strong real-world data for its year-long continuous glucose monitor; Microbot Medical achieved clinical milestones with its robotic endovascular system; LivaNova received FDA approval for its sleep apnea treatment device; and Clover Health showed AI-assisted primary care reduces hospitalizations in high-risk patients.Benzinga · Mar 27, 2026

First Ever Real-World Evidence of Eversense 365 Presented at ATTD Demonstrates Sustained Performance and Positive Impact Throughout One-Year of WearSenseonics presented real-world evidence from 5,059 Eversense 365 CGM users showing sustained performance over a full year with 93.8% average transmitter wear time, mean GMI of 7.14%, and mean TIR of 66%. Over 75% of users achieved hypoglycemic targets. Early data from the twiist AID system combined with Eversense 365 showed even stronger results with mean GMI of 6.79% and TIR of 77%.GlobeNewswire Inc. · Mar 14, 2026

Senseonics Tumbles As Q3 Results And Split Hit StockSenseonics reported Q3 preliminary revenue of $8.1 million, a 91% year-over-year increase, but announced a 1-for-20 reverse stock split that reduced outstanding shares from 816 million to 41 million, causing stock price to drop.Benzinga · Oct 7, 2025

Senseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters’ Option to Purchase Additional Shares, and Closing of Private PlacementSenseonics Holdings, Inc. announced the closing of a public offering of 115 million shares of its common stock, raising $57.5 million in gross proceeds. The company also closed a private placement with Abbott Laboratories, who acquired 40.5 million shares for $20.3 million. The proceeds will be used to fund the launch of Eversense 365 and development of pipeline products.GlobeNewswire Inc. · May 21, 2025

Diabetic Care Device Market Set for Significant Growth with 10.1% CAGRThe global diabetes care devices market is expected to grow from $15.3 billion in 2023 to $26.8 billion by 2029, driven by the rising prevalence of diabetes and the increasing adoption of advanced technologies like continuous glucose monitoring systems.GlobeNewswire Inc. · May 21, 2025

SE

SENSSenseonics Holdings, Inc. Common Stock

SENS

Pay with—

Available Balance0.00

Your PositionYou don't own any SENS yet.

Related Tickers

Earnings